Alembic Pharma gets USFDA nod for Candesartan Cilexetil tablets
New Delhi: Drug firm Alembic Pharma on Wednesday said it has received approval from the US health regulator for Candesartan Cilexetil tablets, used for the treatment of hypertension.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Candesartan Cilexetil tablets USP in the strengths of 4 mg, 8 mg, and 16 mg, Alembic Pharmaceuticals said in a filing to BSE.
The approved product is therapeutically equivalent to the reference listed drug product (RLD), Atacand tablets of ANI Pharmaceuticals.
Quoting to IQVIA data, Alembic Pharma said Candesartan Cilexetil tablets have an estimated market size of USD 22 million for twelve months ending December 2017.
The company currently has a total of 82 ANDA approvals from USFDA, it added.
Also Read: Alembic Pharma gets USFDA nod for insomnia treatment drug
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here